Delayed recognition of HS costs patients time, tissue, and quality of life. The panel examines why episodic flares and atypical presentations are missed and the shame and isolation that follow.
Back
From Tunnels to Treatment: Advancing HS Management
Expert dermatologists examine the burden of hidradenitis suppurativa, including how draining tunnels affect disease severity, quality of life, and treatment response, and discuss how emerging evidence can guide earlier treatment decisions, individualized goals, and long-term outcomes.
From Tunnels to Treatment: Advancing HS Management
Episodes
All
All
Follicular occlusion, anaerobic biofilm, and innate immune activation combine to drive tissue destruction. The panel explains why tunnels sustain inflammation and mark the transition from acute disease to irreversible scarring.
Advertisement
Advertisement
Trending on HCPLive
1
TTR and Systolic Blood Pressure Load Control Improve Recurrent Stroke Risk
2
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
3
Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD
4
ASN Kidney Week 2026 Preview: 8 Late-Breakers We’ll Unpack With the Investigators
5